INDICATION AND IMPORTANT SAFETY INFORMATION
TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.  ...More

TOBI® Podhaler® Supply and Storage

TOBI Podhaler comes in a 28-day (4-week) multipack that has everything your patients need for 1 treatment cycle1

  • 4 weekly packs, each containing 56 capsules (7 blister cards of 8 capsules)
  • 4 disposable Podhaler devices plus 1 backup Podhaler device
  • 4 storage cases plus 1 backup

Not actual size

Use a new disposable Podhaler device and storage case every 7 days. The Podhaler device should always be stored in its case and tightly closed when not in use.1

Information and tips for storing and handling TOBI Podhaler1

DO...
  • Wipe the mouthpiece with a clean, dry cloth
  • Store in a dry place at room temperature (≈77°F); excursions
    permitted to 59°F to 86°F
  • Protect TOBI Podhaler from moisture
  • TOBI Podhaler capsules should be used with the Podhaler device only.
    The Podhaler device should not be used with any other capsules
  • Store TOBI Podhaler capsules in the blister card; each capsule
    should only be removed IMMEDIATELY BEFORE USE
  • Always use the new Podhaler device provided with each weekly pack

A centralized support and access program for TOBI® Podhaler® patients

Learn more

SET TREATMENT EXPECTATIONS

Inform your patients about what to expect while taking TOBI® Podhaler®

Learn more

ADMINISTRATION INFORMATION

Administration information and helpful tips for patients taking TOBI® Podhaler®

Learn more

Share

To share this website with other health care professionals, please choose your email service provider:

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in
1 second
(FEV1) <25% or >80% predicted, or patients colonized with Burkholderia cepacia.